This is relevant because treatments with high doses of ESA have been linked to tumor progression as the erythropoietin receptors are expressed on cancer cells including mammary carcinoma, whereas erythropoietin inhibits pro-inflammatory immune responses of innate immune cells which may hamper cancer control (54–57). The gene discussed is EPO; the disease is breast carcinoma.